| Project/Area Number |
24590962
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Gastroenterology
|
|---|
| Research Institution | Niigata University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
WAKAI Toshifumi 新潟大学, 医歯学系, 教授 (50372470)
TKAMURA Masaaki 新潟大学, 医歯学総合病院, 特任助教 (20422602)
YAMAGIWA Satoshi 新潟大学, 医歯学系, 助教 (10419327)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2013: ¥520,000 (Direct Cost: ¥400,000、Indirect Cost: ¥120,000)
Fiscal Year 2012: ¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
|
|---|
| Keywords | 肝がん / ソラフェニブ / 分子標的薬 / 薬剤耐性 / TGF-beta / sorafenib / hepatocellular carcinoma / drug resistance |
|---|
| Outline of Final Research Achievements |
Sorafenib is a multi-kinase inhibitor for hepatocellular carcinoma. To address whether cytokine-mediated signaling is involved in the drug resistance, hepatoma cells were treated with sorafenib in the presence of several cytokines/growth factors. Obtained results showed that the effect of sorafenib on cell growth was significantly inhibited by TGF-beta. When TGF-beta-treated cells were treated with sorafenib and valproic acid, apoptotic cell numbers were increased as compared with those treated with sorafenib alone. Collectively, combination treatment of valproic acid and sorafenib might improve the efficacy of sorafenib.
|
